[Epidemiological characteristics of tuberculosis patients with primary resistance to major drugs].

A. Pio,J. B. Scocozza,E. Balestrino

1967-06-01

Abstract:

What problem does this paper attempt to address?

Drug Resistance of Mycobacterium in Patients With Pulmonary Tuberculosis inZigong

NING Zhu,LI Qun,ZHOU Shi-xi,HU Yi

2013-01-01

Abstract:Objective To indentify the drug resistant profile of pulmonary TB patients registered in Zigong between April 2010 and August 2011.Methods Newly and previously treated pulmonary TB patients registered in TB dispensaries of 6 districts in Zigong were conducted sensitivity test with four 1st line-drugs of INH(H),RIF(R),EMB(S) and STR(E) by proportion methods.Results Of all the eligible 232 cases,47 was resistant to at least one of the 1st line-drugs,including 15 cases(6.47%) with mono-resistance,7 cases(3.02%) with poly-drug resistance and 25 cases(10.78%) with multidrug resistance.The rate of total drug resistance(DR) and MDR-TB was more likely to happen in previously treated cases compared to the newly treated cases.The rank of DR-rate was H>R>S>E.Conclusion A high rate of drug resistance was observed among TB patients in Zigong.The drug resistance will become the major concern for the anti-TB control activities.Previous medical history is the most crucial factor in the occurrence of drug resistance of TB.
The past, present and future of tuberculosis treatment.

Kefan Bi,Dan Cao,Cheng Ding,Shuihua Lu,Hongzhou Lu,Guangyu Zhang,Wenhong Zhang,Liang Li,Kaijin Xu,Lanjuan Li,Ying Zhang

DOI: https://doi.org/10.3724/zdxbyxb-2022-0454

2023-01-01

Abstract:Tuberculosis (TB) is an ancient infectious disease. Before the availability of effective drug therapy, it had high morbidity and mortality. In the past 100 years, the discovery of revolutionary anti-TB drugs such as streptomycin, isoniazid, pyrazinamide, ethambutol and rifampicin, along with drug combination treatment, has greatly improved TB control globally. As anti-TB drugs were widely used, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of emerged due to acquired genetic mutations, and this now presents a major problem for effective treatment. Genes associated with drug resistance have been identified, including mutations in isoniazid resistance, mutations in rifampin resistance, mutations in pyrazinamide resistance, and mutations in quinolone resistance. The major mechanisms of drug resistance include loss of enzyme activity in prodrug activation, drug target alteration, overexpression of drug target, and overexpression of the efflux pump. During the disease process, may reside in different microenvironments where it is expose to acidic pH, low oxygen, reactive oxygen species and anti-TB drugs, which can facilitate the development of non-replicating persisters and promote bacterial survival. The mechanisms of persister formation may include toxin-antitoxin (TA) modules, DNA protection and repair, protein degradation such as trans-translation, efflux, and altered metabolism. In recent years, the use of new anti-TB drugs, repurposed drugs, and their drug combinations has greatly improved treatment outcomes in patients with both drug-susceptible TB and MDR/XDR-TB. The importance of developing more effective drugs targeting persisters of is emphasized. In addition, host-directed therapeutics using both conventional drugs and herbal medicines for more effective TB treatment should also be explored. In this article, we review historical aspects of the research on anti-TB drugs and discuss the current understanding and treatments of drug resistant and persistent tuberculosis to inform future therapeutic development.
Short-term effects of troxerutin (vitamin P4) on muscle fatigue and gene expression of Bcl-2 and Bax in the hepatic tissue of rats.

M. Zamanian,A. Shamsizadeh,Ali Esmaeili Nadimi,M. Hajizadeh,Fatemeh Allahtavakoli,M. Rahmani,A. Kaeidi,Hamidreza Safari Khalegh,M. Allahtavakoli

DOI: https://doi.org/10.1139/cjpp-2016-0653

2017-02-10

Canadian Journal of Physiology and Pharmacology

Abstract:In the current study, the effects of troxerutin (TRX) on muscle fatigue and gene expression of Bcl-2 and Bax in the hepatic tissue of rats was investigated. Forty male Wistar rats were randomly divided into 4 groups and designated as control and TRX treatment at 75 (TRX75), 150 (TRX150), and 300 mg/kg per day (TRX300). The treated groups and control group received TRX and water orally for 7 days. After an exhaustive swimming test on the 7th day, all animals were euthanized immediately and several biochemical parameters related to fatigue and gene expression of Bcl-2 and Bax in the hepatic tissue were measured. Our results showed that the exhaustion swimming time in the TRX300 groups significantly increased 1.2-fold compared with the control group (P < 0.001). TRX300 significantly reduced ALT (P < 0.05) activity and increased liver SOD activity compared with the control group (P < 0.01). Additionally, TRX significantly reduced the liver mRNA expressions of Bax (P < 0.001) and increased the Bcl-2/Bax ratio (P < 0.001) compared with the control group. Based on our data, TRX possesses anti-apoptotic and hepatoprotective action following exhaustive swimming exercise.
Observation on therapeutic effect of 3HRZ(E)S/6HR for the treatment of pulmonary tuberculosis with primary resistance

ZHANG Li,HUANG Han-ping,WU Chun-yan,ZHANG Qian

2010-01-01

Abstract:Objective To observe the clinical therapeutic effect of 3HRZ(E)S/6HR on primary resistant tuberculosis.Methods All cases chosen were in a randomized way,whose sputum positive tuberculosis of initial treatment,were divided into the study groupⅠ(n=101,the primarily resistant drug was only one kind drug),study groupⅡ(n=45,the primarily resistant drugs were two or more kind drugs)and control group(n=416,all sensitive)by drug sensitivity test.The treatment measures were 3HRZS/6HR.Results The rate of primary resistance in all was 26.0%.When the treatment was completed,the clinical symptom improvement rate,focus absorptivity rate and negative conversion rate in the study groupⅠwere similar to the control group,and the symptom improvement rate was>95%,focus absorptivity rate was>99%,negative conversion rate was>97%,but the study groupⅡwere all worse than in the study groupⅠand control group(P<0.05),and the symptom improvement rate,focus absorptivity rate,negative conversion rate was 71.1%,77.8%and 73.3%.No obvious severe adverse effects were found in the three groups.Conclusion 3HRZS/6HR is not effective to the primary resistant tuberculosis with two or more kind drugs,but is possibly effective to the primary resistant tuberculosis with less than two kind drugs.More attention should be made to the management of chemotherapy,in order to reduce the level of drug-resistance.
Genotypes and drug resistance pattern of Mycobacterium tuberculosis complex among clinically diagnosed pulmonary tuberculosis patients

Alem Alemayehu,Liya Wassie,Dawit Hailu Alemayehu,Bethlehem Adnew,Sebsib Neway,Dessalegn Abeje Tefera,Sosina Ayalew,Elena Hailu,Samuel Ayele,Berhanu Seyoum,Kidist Bobosha,Markos Abebe,Abraham Aseffa,Beyene Petros,Rawleigh Howe

DOI: https://doi.org/10.3389/fpubh.2024.1420685

IF: 5.2

2024-12-03

Frontiers in Public Health

Abstract:The final, formatted version of the article will be published soon. You have multiple emails registered with Frontiers: Please enter your email address: If you already have an account, please login You don't have a Frontiers account ? You can register here Background: Clinically diagnosed pulmonary tuberculosis (TB) (CDPTB) patients account for a huge proportion of TB. However, little is known about the genetic diversity and drug resistance profile of Mycobacterium tuberculosis Complex (MTBC) strains in this group of patients.Unmatched case-control study was conducted among 313 PTB patients to compare the genetic diversity of MTBC and their drug resistance profiles among CDPTB (n=173) and bacteriologically confirmed pulmonary TB (BCPTB) (n=140) patients. Lowenstein-Jensen (LJ) culture, geneXpert and acid fast staining were performed on sputum specimen collected from both CDPTB and BCPTB patients. Spoligotyping, whole genome sequencing (WGS) and phenotypic drug resistance testing (DST) were done for a subset of LJ grown MTBC isolates. Data was analysed by STATA version 17 software and a P-value < 0.05 were considered statistically significant.The proportion of lineage 3 was larger among CDPTB patients (31%, 13/42) compared to BCPTB patients (15%, 11/74) (P-value 0.05). A single lineage 3 strain resistant to all the primary anti-TB drugs was detected in one CDPTB by both DST methods.The observed differences in the genotypes of MTBC isolates between CDPTB and BCPTB patients may be attributed to challenges in the identification of CDPTB that requiresfurther investigation on sequenced genome of the MTBC strains for better understanding and recommendation based on the current finding. . There was also primary drug resistant TB among culture positive CDPTB patients which would be otherwise missed by current national protocols.

public, environmental & occupational health
The problem of syphilis and gonorrhea today.

W. L. Fleming

DOI: https://doi.org/10.1080/00039896.1966.10664574

1966-09-01

Archives of Environmental Health An International Journal

Abstract:
Trends in and Risk Factors for Drug Resistance in Mycobacterium tuberculosis in HIV-Infected Patients

Xiaoqin Le,Xueqin Qian,Li Liu,Jianjun Sun,Wei Song,Tangkai Qi,Zhenyan Wang,Yang Tang,Shuibao Xu,Junyang Yang,Jiangrong Wang,Jun Chen,Renfang Zhang,Zhaoqin Zhu,Yinzhong Shen

DOI: https://doi.org/10.3390/v16040627

2024-04-19

Viruses

Abstract:Trends in and risk factors for drug resistance in Mycobacterium tuberculosis (M. tuberculosis) in human immunodeficiency virus (HIV)-infected patients with active tuberculosis were analyzed. The clinical data of M. tuberculosis and HIV-coinfected patients treated at the Shanghai Public Health Clinical Center between 2010 and 2022 were collected. The diagnosis of tuberculosis was confirmed by solid or liquid culture. The phenotypic drug susceptibility test was carried out via the proportional method, and the resistance to first-line and second-line drugs was analyzed. Logistic regression analysis was performed to identify associated risk factors for drug resistance in M. tuberculosis. Of the 304 patients with a M. tuberculosis-positive culture and first-line drug susceptibility test results, 114 (37.5%) were resistant to at least one first-line anti-tuberculosis drug. Of the 93 patients with first-line and second-line drug susceptibility test results, 40 (43%) were resistant to at least one anti-tuberculosis drug, and 20 (21.5%), 27 (29.0%), 19 (20.4%), 16 (17.2%), and 14 (15.1%) were resistant to rifampicin, streptomycin, ofloxacin, levofloxacin, and moxifloxacin, respectively; 17 patients (18.3%) had multidrug-resistant tuberculosis (MDR-TB). Between 2010 and 2021, the rate of resistance to streptomycin and rifampicin ranged from 14.3% to 40.0% and from 8.0% to 26.3%, respectively, showing an increasing trend year by year. From 2016 to 2021, the rate of resistance to quinolones fluctuated between 7.7% and 27.8%, exhibiting an overall upward trend. Logistic regression analysis showed that being aged <60 years old was a risk factor for streptomycin resistance, mono-drug resistance, and any-drug resistance (RR 4.139, p = 0.023; RR 7.734, p = 0.047; RR 3.733, p = 0.009). Retreatment tuberculosis was a risk factor for resistance to rifampicin, ofloxacin, of levofloxacin (RR 2.984, p = 0.047; RR 4.517, p = 0.038; RR 6.277, p = 0.014). The drug resistance rates of M. tuberculosis to rifampicin and to quinolones in HIV/AIDS patients were high and have been increasing year by year. Age and a history of previous anti-tuberculosis treatment were the main factors associated with the development of drug resistance in HIV/AIDS patients with tuberculosis.

virology
Clinical and operational value of the extensively drug-resistant tuberculosis definition

G. B. Migliori,G. Besozzi,E. Girardi,K. Kliiman,C. Lange,O. S. Toungoussova,G. Ferrara,D. M. Cirillo,A. Gori,A. Matteelli,A. Spanevello,L. R. Codecasa,M. C. Raviglione,

DOI: https://doi.org/10.1183/09031936.00077307

IF: 24.3

2007-10-01

European Respiratory Journal

Abstract:Currently, no information is available on the effect of resistance/susceptibility to first-line drugs different from isoniazid and rifampicin in determining the outcome of extensively drug-resistant tuberculosis (XDR-TB) patients, and whether being XDR-TB is a more accurate indicator of poor clinical outcome than being resistant to all first-line anti-tuberculosis (TB) drugs. To investigate this issue, a large series of multidrug-resistant TB (MDR-TB) and XDR-TB cases diagnosed in Estonia, Germany, Italy and the Russian Federation during the period 1999-2006 were analysed. Drug-susceptibility testing for first- and second-line anti-TB drugs, quality assurance and treatment delivery was performed according to World Health Organization recommendations in all study sites. Out of 4,583 culture-positive TB cases analysed, 361 (7.9%) were MDR and 64 (1.4%) were XDR. XDR-TB cases had a relative risk (RR) of 1.58 to have an unfavourable outcome compared with MDR-TB cases resistant to all first-line drugs (isoniazid, rifampicin ethambutol, streptomycin and, when tested, pyrazinamide), and an RR of 2.61 compared with "other" MDR-TB cases (those susceptible to at least one first-line anti-TB drug among ethambutol, pyrazinamide and streptomycin, regardless of resistance to the second-line drugs not defining XDR-TB). The emergence of extensively drug-resistant tuberculosis confirms that problems in tuberculosis management are still present in Europe. While waiting for new tools which will facilitate management of extensively drug-resistant tuberculosis, accessibility to quality diagnostic and treatment services should be urgently ensured and adequate public health policies should be rapidly implemented to prevent further development of drug resistance.

respiratory system
Analysis of the Results of Tuberculosis Drug Resistance Surveillance in Yuexiu District, Guangzhou City, 2013–2022

Xueqiu Li,Jianxiong Liu

DOI: https://doi.org/10.1002/iid3.70060

2024-11-29

Immunity Inflammation and Disease

Abstract:Introduction The objectives of the study are to understand the drug‐resistant situation and trend of tuberculosis patients in Yuexiu District, Guangzhou City, from 2013 to 2022, and to provide a scientific basis for the development of rational drug‐resistant tuberculosis prevention and control strategies in Guangzhou City. Methods All patients who were diagnosed with active tuberculosis in Guangzhou Chest Hospital from January 1, 2013 to December 31, 2022 were collected as study subjects, and a total of 5191 patients were enrolled in the study. Comprehensive data on the basic characteristics, diagnostic, and therapeutic information of the study subjects were collected. Sputum specimens were subjected to smear, isolation, and culture. Culture‐positive strains of bacteria were identified by bacterial groups. A total of 1659 strains of Mycobacterium tuberculosis (MTB) isolates were obtained. The drug susceptibility test was carried out using the proportionality method on the MTB isolates for nine types of antituberculosis medicines: isoniazid (INH), rifampicin (RFP), ethambutol (EMB), streptomycin (Sm), kanamycin (Km), ofloxacin (Ofx), capreomycin (Cm), propylthioisonicotinamide (Pto), and p‐aminosalicylic acid (PAS). A comparative analysis of the resistance patterns among the strains was conducted. Results A total of 1659 patients with MTB were cultured, revealing 438 drug‐resistant cases. Among these, 255 were monoresistant, 121 were polyresistant, and 62 were multidrug resistant. The overall resistance rate was 26.40% (438/1659), with mono‐resistance rate at 15.37% (255/1659), polyresistance rate at 7.29% (121/1659), and multidrug resistance rate at 3.74% (62/1659). In descending order, the resistance rates of MTB isolates to any of the nine antituberculosis drugs were Sm (12.24%, 203/1659), INH (9.22%, 153/1659), EMB (7.35%, 122/1659), RFP (6.99%, 116/1659), PAS (3.25%, 54/1659), Pto (3.13%, 52/1659), Ofx (2.71%, 45/1659), Cm (2.17%, 36/1659), and Km (2.17%, 36/1659). The differences in resistance rates were statistically significant (p

immunology
Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach

Ivan Barilar,Simone Battaglia,Emanuele Borroni,Angela Pires Brandao,Alice Brankin,Andrea Maurizio Cabibbe,Joshua Carter,Darren Chetty,Daniela Maria Cirillo,Pauline Claxton,David A. Clifton,Ted Cohen,Jorge Coronel,Derrick W. Crook,Viola Dreyer,Sarah G. Earle,Vincent Escuyer,Lucilaine Ferrazoli,Philip W. Fowler,George Fu Gao,Jennifer Gardy,Saheer Gharbia,Kelen Teixeira Ghisi,Arash Ghodousi,Ana Luíza Gibertoni Cruz,Louis Grandjean,Clara Grazian,Ramona Groenheit,Jennifer L. Guthrie,Wencong He,Harald Hoffmann,Sarah J. Hoosdally,Martin Hunt,Zamin Iqbal,Nazir Ahmed Ismail,Lisa Jarrett,Lavania Joseph,Ruwen Jou,Priti Kambli,Rukhsar Khot,Jeff Knaggs,Anastasia Koch,Donna Kohlerschmidt,Samaneh Kouchaki,Alexander S. Lachapelle,Ajit Lalvani,Simon Grandjean Lapierre,Ian F. Laurenson,Brice Letcher,Wan-Hsuan Lin,Chunfa Liu,Dongxin Liu,Kerri M. Malone,Ayan Mandal,Mikael Mansjö,Daniela Vicente Lucena Calisto Matias,Graeme Meintjes,Flávia de Freitas Mendes,Matthias Merker,Marina Mihalic,James Millard,Paolo Miotto,Nerges Mistry,David Moore,Kimberlee A. Musser,Dumisani Ngcamu,Hoang Ngoc Nhung,Stefan Niemann,Kayzad Soli Nilgiriwala,Camus Nimmo,Max O'Donnell,Nana Okozi,Rosangela Siqueira Oliveira,Shaheed Vally Omar,Nicholas Paton,Timothy E. A. Peto,Juliana Maira Watanabe Pinhata,Sara Plesnik,Zully M. Puyen,Marie Sylvianne Rabodoarivelo,Niaina Rakotosamimanana,Paola M. V. Rancoita,Priti Rathod,Esther Rhiannon Robinson,Gillian Rodger,Camilla Rodrigues,Timothy C. Rodwell,Aysha Roohi,David Santos-Lazaro,Sanchi Shah,Grace Smith,Thomas Andreas Kohl,Walter Solano,Andrea Spitaleri,Adrie J. C. Steyn,Philip Supply,Utkarsha Surve,Sabira Tahseen,Nguyen Thuy Thuong Thuong,Guy Thwaites,Katharina Todt,Alberto Trovato,Christian Utpatel,Annelies Van Rie,Srinivasan Vijay,A. Sarah Walker,Timothy M. Walker,Robin Warren,Jim Werngren,Maria Wijkander,Robert J. Wilkinson,Daniel J. Wilson,Penelope Wintringer,Yu-Xin Xiao,Yang Yang,Zhao Yanlin,Shen-Yuan Yao,Baoli Zhu

DOI: https://doi.org/10.1038/s41467-023-44325-5

IF: 16.6

2024-01-12

Nature Communications

Abstract:The World Health Organization has a goal of universal drug susceptibility testing for patients with tuberculosis. However, molecular diagnostics to date have focused largely on first-line drugs and predicting susceptibilities in a binary manner (classifying strains as either susceptible or resistant). Here, we used a multivariable linear mixed model alongside whole genome sequencing and a quantitative microtiter plate assay to relate genomic mutations to minimum inhibitory concentration (MIC) in 15,211 Mycobacterium tuberculosis clinical isolates from 23 countries across five continents. We identified 492 unique MIC-elevating variants across 13 drugs, as well as 91 mutations likely linked to hypersensitivity. Our results advance genetics-based diagnostics for tuberculosis and serve as a curated training/testing dataset for development of drug resistance prediction algorithms.

multidisciplinary sciences
Molecular Mechanisms of Multiple Drug Resistance in Clinical Isolates of Mycobacterium tuberculosis

S. Morris,G. H. Bai,P. Suffys,L. Portillo-Gomez,M. Fairchok,D. Rouse

DOI: https://doi.org/10.1093/infdis/171.4.954

1995-04-01

Abstract:The molecular mechanisms of resistance to streptomycin, rifampin, and isoniazid in 53 Mycobacterium tuberculosis clinical isolates were examined. Twenty-five of 44 streptomycin-resistant strains had mutations in the rpsL gene and 5 of these had rrs gene perturbations. The region of the rpoB gene that is associated with resistance to rifampin was altered in 28 of 29 rifampin-resistant strains. Mutations in known genetic markers of isoniazid resistance were detected in 25 of 42 isoniazid-resistant isolates: 20 strains had katG gene alterations and 5 had perturbations in the inhA operon. Of the 20 multiply resistant strains with reduced sensitivity to streptomycin, rifampin, and isoniazid, 11 had mutations in genetic markers associated with resistance to each of these three drugs. These studies suggest that the primary mechanism of multiple drug resistance in tuberculosis is the accumulation of mutations in individual drug target genes.

immunology,infectious diseases,microbiology
Analysis of drug resistance of 589 Mycobacterium Tuberculosis strains for 10 type antituberculosis drugs

LIU Hou-ming,ZHAN Nen-yong,CHEN Jian-bo,XIAO Yan-yu,LUO Kai,WU Chi,SHAN Wan-shui

DOI: https://doi.org/10.3969/j.issn.1009-6663.2011.04.032

2011-01-01

Abstract:Objective To analyze the drug resistance of Mycobacterium Tuberculosis(M.TB) for 10 type antituberculosis drugs in Shenzhen Third People′s Hospital.MethodsAll kinds of samples were cultured with MB/Bact 240 and improved L-J medium,clinical isolated M.TB strains were tested with absolute concentration method for 10 type antituberculosis drugs,including RFP、INH、EMB、SM、RFT、TH、OFL、CPM、KM and PAS.Results589 strains M.TB were isolated in 1722 samples,the positive rate of M.TB is 34.2%(589/1722),the total ratio of drug resistant for 10 type antituberculosis drugs is 38%(224/589);Of 10 type antituberculosis drugs,the highest resistant rate is SM(17.1%),the lowest is PAS(3.4%).Of 55 strains multidrug resistant tuberculosis(MDR-TB),the highest resistant rate is RFT(94.5%),the lowest is KM(3.4%) and PAS(3.4%),3 strains MDR-TB are resistant to another 8 type antituberculosis drugs.ConclusionsClinical isolated M.TB of Shenzhen area is very serious on drug resistant.Monitoring of resistance to antituberculosis drugs must be strengthened;Choosing reasonable and efficient therapy on guideline of antituberculosis susceptibility test.
Clinical Characteristics and Outcome Predictors in Drug-Resistant Tuberculosis: A Comprehensive Analysis

Imtiaz Pasha,Ashraf ALakkad

DOI: https://doi.org/10.9734/air/2024/v25i51138

2024-09-02

Advances in Research

Abstract:Background: Drug-resistant tuberculosis (DR-TB) poses significant challenges to public health, with poor outcomes frequently observed in affected patients. This study aims to evaluate the characteristics and factors associated with poor outcomes in patients with drug-resistant pulmonary tuberculosis at Liwa Hospital from January 2018 to May 2023. Methods: A retrospective, cross-sectional single-center analysis was conducted on 408 patients admitted to Liwa Hospital. Among these, 28 patients diagnosed with drug-resistant tuberculosis (DR-TB) were selected for detailed analysis based on their treatment outcomes and clinical data. Inclusion criteria encompassed patients aged 18 years or older with confirmed drug-resistant TB, while patients younger than 18, those with latent tuberculosis, and those with extra-pulmonary tuberculosis were excluded. Results: The majority of patients were between 18-40 years old (60.7%), predominantly male (85.7%), and Asian (96.4%). Comorbidities included diabetes (46.4%) and hypertension (21.4%). Clinical characteristics revealed cough (28.6%) and fever with cough (7.1%) as common symptoms. Primary resistance was observed in 92.9% of cases, with 96.4% being newly diagnosed TB cases. Adverse drug events were minimal, with 7.1% experiencing nausea and vomiting. Radiological findings showed unilateral TB in 53.6% and cavitary TB in 57.1% of cases. Laboratory analysis indicated elevated HbA1c (9.83 ± 3.25), CRP (25.94 ± 5.16 mg/L), and white blood cell count (9.94 ± 4.59 x 10^9 cells/L). Rifampicin resistance was the most prevalent (42.9%), followed by isoniazid resistance (25.0%). Regarding treatment outcomes, age, hypertension, and diabetes mellitus were found to be significantly associated with poor outcomes in patients (p=0.05). Conclusion: The study identified significant associations between treatment outcomes and age, hypertension, and diabetes status, with higher proportions of poor outcomes observed in patients. Comprehensive management strategies targeting these factors are essential to improve outcomes in patients with drug-resistant TB. Further research is warranted to develop tailored interventions for this population.
Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.

Peng Xu,Jie Wu,Chongguang Yang,Tao Luo,Xin Shen,Yangyi Zhang,Chijioke A Nsofor,Guofeng Zhu,Brigitte Gicquel,Qian Gao

DOI: https://doi.org/10.1016/j.tube.2016.02.008

2016-01-01

Abstract:Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug, however, there are relatively few available data on PZA resistant (PZA-R) rate in China. From June 2009 to June 2012, we selected 493 isolates from five field settings in China to investigate PZA-R by pncA gene sequencing. The result showed that PZA-R rate was 1.0% (2/196) among pan-susceptible isolates, 3.1% (4/130) among isoniazid (INH) mono-resistant isolates, 14.0% (6/43) among rifampin (RIF) mono-resistant isolates and 43.5% (54/124) among multidrug resistant (MDR) isolates. MDR tuberculosis (TB), RIF mono-resistance, and retreatment were found to be risk factors for PZA-R. Newly diagnosed PZA-R TB patients and clustered isolates with identical pncA mutations indicate that transmission of PZA-R isolates plays an important role in emergence of PZA-R TB. The results suggest that, it is necessary to conduct PZA susceptibility test among MDR isolates and modify the treatment regimens accordingly.
Drug hypersensitivity in drug-resistant tuberculosis

Zeynep Yegin Katran,İsmet Bulut,Aylin Babalık,Metin Keren,Fatma Merve Tepetam,Selver Seda Mersin,Cihan Örçen,Tuğçe Yakut,Dilek Yavuz

DOI: https://doi.org/10.1016/j.waojou.2023.100778

IF: 5.516

2023-05-01

World Allergy Organization Journal

Abstract:Objective: To evaluate drug resıstant tuberculosis patients who developed drug hypersensitivity to antituberculosis drug.Methods: This was a retrospective study. The primary aim of the study is to determine the demographic and clinical characteristics of patients who develop drug hypersensitivity in drug resistant tuberculosis patients. The secondary aim of the study is to examine the treatment results. Demographic features, tuberculosis diagnostic indicator, clinical signs of developing hypersensitivity reaction, reaction time, and treatment were evaluated.Results: A total of 25 patients were included in the study. The prevalence of hypersensitivity in drug resistance patients was 11.9%. Twelve (48%) of the cases were women. Mean age (mean ± SD) was 37.24 ± 14.44 years; early type hypersensitivity reaction in 13 (52%). Three patients were isoniazid resistant; 19 patients were multidrug-resistant (MDR); 2 patients were pre-extensive drug resistant (Pre-XDR), 1 patient was extensive drug resistance (XDR) tuberculosis. The most common skin findings were maculopapular eruption and urticaria. But also we had seen ısole angıodema, urtıcarıa and angıoedema, erythema multıforme, lıchenoıd drug eruptıon and drug rash with eosinophilia and systemic symptoms. In patients who developed a hypersensitivity reaction, the responsible agent was identified in 14 cases in total. Among the drugs, pyrazinamide, ethambutol, moxifloxacin, amikacin, para amino salicylic, prothionamide, and cycloserine are the responsible agents. When evaluated in terms of treatment results, 15 (60%) patients successfully completed the treatment.Conclusion: Our study is the first study in the literature that evaluated the drug hypersensitivity in drug resıstance tuberculosis patients. Drug hypersensitivity that develops with tuberculosis treatment may lead to discontinuation or change in treatment. İt can cause treatment failure, drug resistance, relapse, and even death. In resistant tuberculosis, the already existing resistance pattern may become more difficult to treat. Success can be achieved with the right management in these patients who have few treatment options, more drug side effects, and high treatment failure rates. The established regimen should be curative and prevent recurrence.

immunology,allergy
Phenotypic and Genotypic Drug Resistance of Mycobacterium tuberculosis Strains Isolated from HIV-Infected Patients from a Third-Level Public Hospital in Mexico

Daniel Valencia-Trujillo,Amanda Marineth Avila-Trejo,Rocío Liliana García-Reyes,Luis Narváez-Díaz,Mario Alberto Mújica-Sánchez,Addy Cecilia Helguera-Repetto,Eduardo Becerril-Vargas,Mónica Maribel Mata-Miranda,Sandra Rivera-Gutiérrez,Jorge Francisco Cerna-Cortés

DOI: https://doi.org/10.3390/pathogens13020098

IF: 3.7

2024-01-23

Pathogens

Abstract:Background: Drug-resistant tuberculosis (TB) is associated with higher mortality rates in patients with human immunodeficiency virus (HIV). In Mexico, the number of deaths due to TB among the HIV-positive population has tripled in recent years. Methods: Ninety-three Mycobacterium tuberculosis strains isolated from the same number of HIV-infected patients treated in a public hospital in Mexico City were studied to determine the drug resistance to first- and second-line anti-TB drugs and to identify the mutations associated with the resistance. Results: Of the 93 patients, 82.7% were new TB cases, 86% were male, and 73% had extrapulmonary TB. Most patients (94%) with a CD4 T-lymphocyte count <350 cells/mm3 were associated with extrapulmonary TB (p 350 cells/mm3 were associated with pulmonary TB (p = 0.0011). Eighty-two strains were pan-susceptible, four mono-resistant, four poly-resistant, two multidrug-resistant, and one was extensively drug-resistant. In the rifampicin-resistant strains, rpoB S531L was the mutation most frequently identified, whereas the inhA C15T and katG S315T1 mutations were present in isoniazid-resistant strains. The extensively drug-resistant strain also contained the mutation gyrA D94A. Conclusions: These data highlight the need to promptly diagnose the drug resistance of M. tuberculosis among all HIV-infected patients by systematically offering access to first- and second-line drug susceptibility testing and to tailor the treatment regimen based on the resistance patterns to reduce the number of deaths in HIV-infected patients.

microbiology
Impact of Genotypic and Phenotypic Resistance to Second-Line Anti-Tuberculosis Drugs on Treatment Outcomes in Multidrug-Resistant Tuberculosis in China.

Yi Hu,Xubin Zheng,Zhu Ning,Qun Li,Zhengdong Zhang,Sven Hoffner

DOI: https://doi.org/10.1016/j.ijmyco.2016.11.007

2016-01-01

International Journal of Mycobacteriology

Abstract:BACKGROUND:Despite the strong association between drug resistance and genetic mutations, the value of molecular diagnosis of drug resistance to guide the treatment of multidrug-resistant tuberculosis (MDR-TB) remains unclear. This is particularly relevant in resource-limited areas, in which it is difficult to implement the drug susceptibility test. Here, we focused on the association of drug susceptibility phenotype and genotype with treatment outcomes in patients with MDR-TB.METHODS:In a prospective cohort study, we enrolled 252 consecutive patients with confirmed MDR-TB between 2010 and 2013, and outcomes were followed-up over the 24-month treatment course in terms of clinical manifestation and sputum conversion. All the isolates were tested for phenotypic susceptibility to second-line drugs in the Mycobacteria Growth Indicator Tube based system, and genotypic mutations were assessed by DNA sequencing.RESULTS:Among the 252 MDR-TB isolates, 88 (34.9%) were resistant to fluoroquinolones and/or second-line injectable drugs, of which 65 (73.9%) harbored a mutation in drug resistance-related genes (gyrA, rrs and eis). In addition, 85 individuals (33.7%) were also resistant to pyrazinamide, with 87.1% containing the pncA mutation. Of 252 MDR-TB patients, 207 (82.1%) had known outcomes and 45 (17.9%) were lost to follow-up. Among those with known outcomes, treatment succeeded in 85.8% with plain MDR-TB, 69.7% with initial resistance to either a fluoroquinolone or second-line injective drugs, 37.5% with initial resistance to pyrazinamide, 29.3% with initial extensively drug resistance. In contrast, among those with known outcomes, treatment success and culture conversion depends on the susceptibility to drug especially for pyrazinamide and fluoroquinolones. In multivariate analysis, pyrazinamide resistance and its related pncA gene mutation were independently associated with a lower risk of culture conversion on at 8weeks and treatment success, while fluoroquinolone resistance was negatively correlated with treatment success. Besides, specific treatment, patient and program variables were also associated with treatment outcome.CONCLUSION:Drug susceptibility testing for pyrazinamide and fluoroquinolones together with genetic information appears to provide a clinically useful indicator of the treatment outcome of MDR-TB in China.
Transmission is a Noticeable Cause of Resistance among Treated Tuberculosis Patients in Shanghai, China

Chijioke A. Nsofor,Qi Jiang,Jie Wu,Mingyu Gan,Qingyun Liu,Tianyu Zuo,Guofeng Zhu,Qian Gao

DOI: https://doi.org/10.1038/s41598-017-08061-3

IF: 4.6

2017-01-01

Scientific Reports

Abstract:It is generally believed that drug resistance among treated tuberculosis (TB) patients is as a result of acquired drug resistance due to inappropriate treatment. Previous studies have shown that primary drug resistance caused by transmission also plays a role among treated cases. Differentiating the two types of drug resistance will help in developing appropriate strategies for control of drug resistant tuberculosis. In this study, we tested the hypothesis that drug resistance among treated TB patients is mainly caused by primary resistance rather than acquired resistance. Defining resistance profiles by molecular drug susceptibility test, we used Unit Variable Number Tandem Repeats (VNTR) to genotype and Whole Genome Sequencing (WGS) to confirm the accordance of the first and last Mycobacterium tuberculosis isolates from treated pulmonary TB patients in Shanghai from 2009-2015. Among 81 patients with increasing drug resistance, out of 390 patients enrolled, paired isolates from 59.3% (48/81) had different VNTR patterns indicating primary drug resistance. Our results have demonstrated that primary resistance due to exogenous reinfection is the major cause of drug resistance among treated TB patients in Shanghai; thus, strategies aimed at preventing and interrupting transmission are urgently needed to effectively reduce the epidemic of drug resistant tuberculosis.
Primary drug-resistance is the main cause of drug-resistant tuberculosis]

Jian Mei,Zhen Xue,Xin Shen,Guo-miao Shen,Xiao-hong Gui,Mei Shen,Qian Gao

DOI: https://doi.org/10.3760/j:issn:1001-0939.2006.02.002

2006-01-01

Abstract:To investigate the main cause of drug-resistant tuberculosis.Clinic isolates of Mycobacterium tuberculosis from 1996 to 2004 in Shanghai were analyzed and the proportion of isolates from new cases (the proxy of primary drug-resistance) and retreatment cases (the proxy of acquired drug-resistance) were calculated. Mycobacterial interspersed repetitive units (MIRU) genotyping was performed and analyzed on pairs of isolates of Mycobacterium tuberculosis from 16 recurrent patients with drug-resistant tuberculosis.Of all 8 120 isolates of Mycobacterium tuberculosis from new cases, 707 isolates (8.7%) were drug resistant. Of all 610 isolates from retreatment cases, 150 isolates (24.6%) were drug resistant. Primary drug resistance accounted for 82.5% (707/857) of all drug resistant isolates. Based on the MIRU genotypes, 13 of all 16 recurrent drug-resistant patients were reinfected with new drug-resistant strain of Mycobacterium tuberculosis.Primary drug-resistance is the main cause of drug-resistant tuberculosis.
Machine learning reveals that Mycobacterium tuberculosis genotypes and anatomic disease site impacts drug resistance and disease transmission among patients with proven extra-pulmonary tuberculosis

Doctor B Sibandze,Beki T Magazi,Lesibana A Malinga,Nontuthuko E Maningi,Bong-Akee Shey,Jotam G Pasipanodya,Nontombi N Mbelle

DOI: https://doi.org/10.1186/s12879-020-05256-4

2020-07-31

Abstract:Background: There is a general dearth of information on extrapulmonary tuberculosis (EPTB). Here, we investigated Mycobacterium tuberculosis (Mtb) drug resistance and transmission patterns in EPTB patients treated in the Tshwane metropolitan area, in South Africa. Methods: Consecutive Mtb culture-positive non-pulmonary samples from unique EPTB patients underwent mycobacterial genotyping and were assigned to phylogenetic lineages and transmission clusters based on spoligotypes. MTBDRplus assay was used to search mutations for isoniazid and rifampin resistance. Machine learning algorithms were used to identify clinically meaningful patterns in data. We computed odds ratio (OR), attributable risk (AR) and corresponding 95% confidence intervals (CI). Results: Of the 70 isolates examined, the largest cluster comprised 25 (36%) Mtb strains that belonged to the East Asian lineage. East Asian lineage was significantly more likely to occur within chains of transmission when compared to the Euro-American and East-African Indian lineages: OR = 10.11 (95% CI: 1.56-116). Lymphadenitis, meningitis and cutaneous TB, were significantly more likely to be associated with drug resistance: OR = 12.69 (95% CI: 1.82-141.60) and AR = 0.25 (95% CI: 0.06-0.43) when compared with other EPTB sites, which suggests that poor rifampin penetration might be a contributing factor. Conclusions: The majority of Mtb strains circulating in the Tshwane metropolis belongs to East Asian, Euro-American and East-African Indian lineages. Each of these are likely to be clustered, suggesting on-going EPTB transmission. Since 25% of the drug resistance was attributable to sanctuary EPTB sites notorious for poor rifampin penetration, we hypothesize that poor anti-tuberculosis drug dosing might have a role in the development of resistance.

[Epidemiological characteristics of tuberculosis patients with primary resistance to major drugs].

Drug Resistance of Mycobacterium in Patients With Pulmonary Tuberculosis inZigong

The past, present and future of tuberculosis treatment.

Short-term effects of troxerutin (vitamin P4) on muscle fatigue and gene expression of Bcl-2 and Bax in the hepatic tissue of rats.

Observation on therapeutic effect of 3HRZ(E)S/6HR for the treatment of pulmonary tuberculosis with primary resistance

Genotypes and drug resistance pattern of Mycobacterium tuberculosis complex among clinically diagnosed pulmonary tuberculosis patients

The problem of syphilis and gonorrhea today.

Trends in and Risk Factors for Drug Resistance in Mycobacterium tuberculosis in HIV-Infected Patients

Clinical and operational value of the extensively drug-resistant tuberculosis definition

Analysis of the Results of Tuberculosis Drug Resistance Surveillance in Yuexiu District, Guangzhou City, 2013–2022

Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach

Molecular Mechanisms of Multiple Drug Resistance in Clinical Isolates of Mycobacterium tuberculosis

Analysis of drug resistance of 589 Mycobacterium Tuberculosis strains for 10 type antituberculosis drugs

Clinical Characteristics and Outcome Predictors in Drug-Resistant Tuberculosis: A Comprehensive Analysis

Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.

Drug hypersensitivity in drug-resistant tuberculosis

Phenotypic and Genotypic Drug Resistance of Mycobacterium tuberculosis Strains Isolated from HIV-Infected Patients from a Third-Level Public Hospital in Mexico

Impact of Genotypic and Phenotypic Resistance to Second-Line Anti-Tuberculosis Drugs on Treatment Outcomes in Multidrug-Resistant Tuberculosis in China.

Transmission is a Noticeable Cause of Resistance among Treated Tuberculosis Patients in Shanghai, China

Primary drug-resistance is the main cause of drug-resistant tuberculosis]

Machine learning reveals that Mycobacterium tuberculosis genotypes and anatomic disease site impacts drug resistance and disease transmission among patients with proven extra-pulmonary tuberculosis